Noxopharm Ltd. · ASX:NOX
Noxopharm — H.C. Wainwright 23rd Annual Global Investment Conference 2021
16 slides from Noxopharm's conference presentation, Sep 15, 2021
Slide 1: H.C. Wainwright 23rd Annual Global Investment Conference
H.C. Wainwright 23rd Annual Global Investment Conference 13-15 September 2021
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Noxopharm Limited (NOX or the looking statements contained in this document will actually occur or that the Company). It should not be considered as an offer or invitation to subscribe for, assumptions on which those statements are based are exhausti
Slide 3: Therapies targeting single errors are restricted in their benefit
Chronic cancer inflammation Human degenerative disease Autoimmunity Involves multiple mutations, Neurodegenerative diseases multiple errors Therapies targeting single errors Single drugs targeting multiple errors are restricted in their benefit OR The choice is polypharma Copyright Noxopharm 2021
Slide 4: Introducing idronoxil (Veyonda®)
Introducing A novel multi kinase and membrane NAD(P)H-oxidase idronoxil (Veyonda®) inhibitor targeting aberrant protein behaviour Protein thiol- Protein Primary biochemical targets phosphorylation, Sphingomyelin disulfide dephosphorylation, pathway exchange dimerisation Primary biological outcomes P
Slide 5: Four R&D Businesses in One Company
Four R&D Businesses in One Company Veyonda® Cancer Research Veyonda® Pipeline Chronic inflammatory Cancer treatment Cancer growth Septic shock diseases/autoimmune enhancement factor inhibitors diseases Copyright Noxopharm 2021
Slide 6: Cancer treatment enhancement programs
Veyonda® Cancer treatment enhancement IONIC - checkpoint inhibitor therapy DARRT - radiotherapy Programs A revolutionary concept in cancer therapy involving a drug (Veyonda®) with multiple CEP - chemotherapy mechanisms of action that aims to boost the effectiveness of other standard anti-cancer LuPI
Slide 7: IONIC - checkpoint inhibitor therapy
Veyonda® Cancer treatment enhancement IONIC Checkpoint inhibitor therapy Idronoxil • Inhibits sphingosine Challenge kinase 1, blocking S1P • PD-1 inhibitor therapy production relies on the presence of • → upregulation of CD4+ effector T-cells to take and CD8+ T-cells advantage of drug action • ~95%
Slide 8: DARRT - external beam radiotherapy
Veyonda® Cancer treatment enhancement DARRT External beam radiotherapy Challenge • Low-dose EBRT triggers an immune response within single irradiated Idronoxil tumours • On very rare occasions, • Inhibits autophagy Phase II DARRT trial • Activates immune function that immune response shifts from a l
Slide 9: LuPIN - radioligand therapy
Veyonda® Cancer treatment enhancement LuPIN Radioligand therapy Challenge Idronoxil • Effectiveness of targeted • Blocks cell division (G2M) radiotherapy by radioligands → greater DNA damage dependent on expression of • Blocks DNA repair LuPIN phase I/II study antigen target on cancer (topoisomerase
Slide 10: CEP - chemotherapy
Veyonda® Cancer treatment enhancement CEP Chemotherapy Idronoxil • Blocks external membrane Challenge NADH oxidase function → High rates of inherent and interfers with protein folding acquired resistance in most • Blocks S1P expression → tumour types to cytotoxic chemotherapies due to over- reductio
Slide 11: Cancer Research Pipeline: 'Helper' growth factor inhibitors
Cancer Research Pipeline ‘Helper’ growth factor inhibitors Brain cancer (GBM) Programs Many cancers, particularly the Pancreatic cancer highly aggressive cancers, co- opt supporting healthy cells to supply growth factors that drive cancer cell growth. Noxopharm has identified a novel family of drugs
Slide 12: Brain cancer program
Cancer Research Pipeline Brain cancer program Noxopharm and U.S. National Cancer Institute to Collaborate on Promising New Approach to Treatment of Brain Cancer* Major discovery by NOX scientists of new family of molecules ➡ Killing brain cancer cells directly ➡ Blocking ‘helper’ growth signals *ASX
Slide 13: Septic shock: Phase I pilot trial completed
Veyonda® Septic shock Idronoxil • Potent inhibitor of cGAS- Phase I pilot trial completed STING /TBK1 signaling pathway → blocking • Hospitalised patients with moderate to release of pro- severe ARDS requiring supplementary O2 inflammatpry cytokines • Veyonda added to SOC • Upregulates NK and T-cell
Slide 14: Chronic inflammatory diseases/autoimmune diseases
Chronic inflammatory diseases/autoimmune diseases Chronic inflammation Pharmorage, a collaboration Programs between NOX and Hudson Institute of Medical Research. Autoimmunity Based on identification of a new family of drug compounds with highly selective activity against cGAS-STING/TBK1 STING/TBK1 a
Slide 15: Key Metrics and Anticipated News Flow
Key Metrics (at 8 September 2021) Anticipated News Flow (next 6 months) Market cap A$153m Progress in IONIC-1, DARRT-2 & CEP-2 Share price A$0.53c Phase 2 COVID-19 clinical trial update Oncology drug pipeline progress Issued shares ~288.3m Pharmorage drug discovery progress Cash (at 30/6/21) A$26.8
Slide 16: For further information
For further information: info@noxopharm.com www.noxopharm.com @Noxopharm
Noxopharm — H.C. Wainwright 23rd Annual Global Investment Conference 2021 on 6ix